logo
Plus   Neg
Share
Email

AVEO, Bristol Myers To Evaluate Fotivda - Opdivo In Phase 3 Trial In Relapsed Renal Cell Carcinoma

AVEO Oncology (AVEO) said Friday that it reached a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate Fotivda or tivozanib in combination with Opdivo or nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, in the pivotal Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma or RCC following prior immunotherapy exposure.

Fotivda is an oral, next-generation vascular endothelial growth factor tyrosine kinase inhibitor approved for the treatment of adult patients with relapsed or refractory advanced RCC following two or more prior systemic therapies.

It is expected that the trial will enroll about 326 patients with advanced RCC who have progressed following prior immunotherapy treatment.

The study plans to enroll across clinical sites in the United States, Europe, and Latin America. Patients will be randomized 1:1 to receive either Fotivda (1.34 mg/QD for 21 days followed by 7 days off treatment) in combination with Opdivo (480 mg every 4 weeks) or Fotivda alone.

The TiNivo-2 study's primary endpoint will assess progression free survival, with key secondary endpoints to include overall survival, overall response rate and duration of response, and safety.

Bristol Myers Squibb will provide OPDIVO clinical drug supply for the study. AVEO will serve as the study sponsor and will be responsible for costs associated with the trial execution.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast-food giant McDonald's said it will be raising hourly wages for more than 36,500 hardworking employees at McDonald's-owned restaurants by an average of 10 percent to make it among the industry-leading pay and benefits package. These increases, which have already begun, will be rolled out over the next several months. Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints,... General Mills Inc. (GIS) agreed to buy Tyson Foods' (TSN) pet treats business for $1.2 billion in cash, the companies said in a statement on Friday. The transaction includes the Nudges, Top Chews and True Chews brands. General Mills will also acquire a manufacturing facility in Independence, Iowa.
Follow RTT